GRTX
Galera Therapeutics, Inc.Company Information
- Company Name
- Galera Therapeutics, Inc.
- CIK
- CIK0001563577
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- GRTX: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- GRTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-12-30
- Last sale
- 2025-11-20
- Shares purchased (TTM)
- 7,644,932
- Shares sold (TTM)
- 70,000
Institutional Sentiment
- As of
- 2024-06-30
- Institutional shares owned
- 4,414
- Shares outstanding
- 54,392,170
- Ownership
- 0.01%
Earnings Market Reaction
- Filing date
- 2026-05-14
- Price on filing date
- —
- 1-month reaction
- -5.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 6 | 6 | 4 | 5 | 7 | 8 | 8 | 11 | 13 | 18 | 24 | 24 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | - | 0 | 4 | 14 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 6 | 7 | 5 | 6 | 8 | 10 | 9 | 12 | 15 | 22 | 31 | 42 | ||||||
| Restricted Cash | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 3 | 3 | 3 | ||||||
| Restricted Cash Current | - | - | - | - | - | - | - | - | - | 0 | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | ||||||
| Property Plant And Equipment Net | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Indefinite Lived Intangible Assets Excluding Goodwill | - | - | - | - | - | 0 | 0 | 2 | 2 | 2 | 2 | 2 | ||||||
| Assets | 6 | 7 | 5 | 6 | 8 | 10 | 9 | 16 | 20 | 26 | 38 | 48 | ||||||
| Goodwill | - | - | - | - | - | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
Liabilities | ||||||||||||||||||
| Liabilities | 1 | 1 | 152 | 151 | 152 | 154 | 152 | 154 | 154 | 157 | 164 | 163 | ||||||
| Preferred Stock Value | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Debt And Capital Lease Obligations Current | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Payable Current | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 4 | 6 | ||||||
Liabilities Current | ||||||||||||||||||
| Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 9 | 8 | ||||||
| Liabilities Current | - | 1 | 1 | 0 | 1 | 2 | 1 | 2 | 2 | 5 | 13 | 14 | ||||||
| Royalty Guarantees Commitments Amount | - | 0 | 151 | 151 | 151 | 151 | 151 | 151 | 151 | 151 | 150 | 148 | ||||||
| Warrants And Rights Outstanding | - | 0 | 0 | 0 | 0 | 1 | - | - | - | 0 | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 1 | 4 | -149 | -148 | -147 | -148 | -143 | -138 | -135 | -131 | -127 | -115 | ||||||
| Additional Paid In Capital Common Stock | 310 | 311 | 311 | 311 | 311 | 308 | 308 | 308 | 307 | 306 | 305 | 302 | ||||||
| Deferred Tax Liabilities Derivatives | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -309 | -307 | -460 | -459 | -458 | -456 | -451 | -446 | -442 | -437 | -432 | -417 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Liabilities And Stockholders Equity | 6 | 7 | 5 | 6 | 8 | 10 | 9 | 16 | 20 | 26 | 38 | 48 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 75 | 75 | 75 | 75 | 75 | 75 | 54 | 54 | 54 | 54 | 54 | 44 | ||||||
| Shares Outstanding | 75 | 75 | 75 | 75 | 75 | 75 | 54 | 54 | 54 | 54 | 54 | 44 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialGalera Therapeutics, Inc. (GRTX) — SEC Financial Statements & Analysis
Galera Therapeutics, Inc. (GRTX) is a pharmaceutical preparations company, incorporated in DE. Galera Therapeutics, Inc. trades on OTC as: GRTX. Galera Therapeutics, Inc. (GRTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-14. Based on that filing, On profitability, Galera Therapeutics, Inc. posts a Return on Equity (ROE) of -204.66% and a Return on Assets (ROA) of 2168.75%. Per share, it reports EPS of $1.52, diluted EPS of $1.52, free cash flow per share of $-0.05, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -1040.26% year-over-year and EPS growth of -1040.26% year-over-year. On the balance sheet, it maintains a current ratio of 11.00x, a quick ratio of 9.88x, working capital of $6.45M, a debt-to-equity ratio of 0.16x, a debt ratio of 0.09, an interest coverage ratio of -28.18x, free cash flow of $-4.69M (TTM), and net debt of $-5.50M. Figures sourced from SEC EDGAR.
- EPS TTM
- $1.52
- ROE TTM
- -204.66%
- ROA TTM
- 2168.75%
- Debt To Equity
- 0.16x
- Free Cash Flow TTM
- $-4.69M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Galera Therapeutics, Inc. in?
Galera Therapeutics, Inc. (GRTX) operates in the Pharmaceutical Preparations industry.
What exchange does GRTX trade on?
Galera Therapeutics, Inc. (GRTX) trades on the OTC.
Where is Galera Therapeutics, Inc. incorporated?
Galera Therapeutics, Inc. is incorporated in DE.
When was Galera Therapeutics, Inc. (GRTX)'s most recent SEC filing?
Galera Therapeutics, Inc. (GRTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-14.
What is GRTX's EPS (earnings per share)?
Galera Therapeutics, Inc. (GRTX)'s trailing twelve month EPS is $1.52 as of 2026-03-31.
What is GRTX's ROE (return on equity)?
Galera Therapeutics, Inc. (GRTX)'s trailing twelve month Return on Equity (ROE) is -204.66% as of 2026-03-31.
What is GRTX's ROA (return on assets)?
Galera Therapeutics, Inc. (GRTX)'s trailing twelve month Return on Assets (ROA) is 2168.75% as of 2026-03-31.